Correspondence 0001104659-23-017723 from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 9, 2023 · CIK: 0001671502 · Accession: 0001104659-23-017723
AI Filing Summary & Sentiment
File numbers found in text: 333-269543
Letter
Re: Quoin Pharmaceuticals Ltd.
February 9, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-269543
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE GLOBAL PARTNERS, as Lead Placement Agent, hereby joins Quoin Pharmaceuticals Ltd. (the “Company”) in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1, as amended (File No. 333-269543) (the “Registration Statement”), to become effective on Friday, February 10, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel Blank Rome LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated February 8, 2023, are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The Lead Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
Show Raw Text
CORRESP
1
filename1.htm
February 9, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Quoin Pharmaceuticals Ltd.
Registration Statement
on Form S-1
File No. 333-269543
Ladies and Gentlemen:
In accordance with
Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE
GLOBAL PARTNERS, as Lead Placement Agent, hereby joins Quoin Pharmaceuticals Ltd. (the “Company”) in requesting that the Securities
and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1, as amended (File No. 333-269543)
(the “Registration Statement”), to become effective on Friday, February 10, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter
as practicable, or at such other time as the Company or its outside counsel Blank Rome LLP, request by telephone that such Registration
Statement be declared effective.
Pursuant to Rule 460
of the General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated February
8, 2023, are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be
reasonable to secure adequate distribution of the Preliminary Prospectus.
The Lead
Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the
Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
By:
/s/ Thomas J. Higgins
Name:
Thomas J. Higgins
Title:
Managing Director